Lower-dose chemo for children with new leukemia
This trial tests a lower starting dose of chemotherapy for children newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. The goal is to see if a reduced dose is still effective and safer for children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or younger.
- You must have been newly diagnosed with AML, not a relapse.
- You cannot have a specific subtype called promyelocytic leukemia.
- You cannot have Down syndrome and be younger than 4 years old.
- Your AML must not have been caused by a previous cancer treatment or a prior blood disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
This trial tests whether a personalized, lower-dose chemotherapy plan can help adults with acute lymphoblastic leukemia (ALL) who are frail or have other health problems. It aims to improve survival by adjusting the dose to what each person can handle.
This study tests a treatment plan for children under 18 with a new diagnosis of acute myeloid leukemia (AML). It aims to provide effective therapy based on standard guidelines, and may include children with certain blood or bone marrow findings even if tests are limited.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hear when a new Pediatric Acute Myeloid Leukemia Induction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.